We also collaborate on workshops with industry. There is a fundamental need to educate professionals about treatments and generate awareness of the patient view, and through…
In Conversation
It is this kind of contribution that has accelerated us to number five on the pharma UK rankings but quite frankly, working hard every day to…
“The UK is an international bridge and provides access to Europe, America and Asia. Its Commonwealth history and global presence have substantial advantages. Besides its location…
We are all proud of the work we do to help the amazing people who are affected by rare disease and yet continue to strive for…
"Today, our three sites are thus very complementary, we do not single out a lead site. In Japan we continue enhancing our technical development, while we…
"The philosophy behind the Cobra development is to work closely with our customers and expand through their future commitment to support shareholder investment and government grants."
"The regulatory environment we encountered has been unbelievably helpful ... To us, a good relationship with authorities, based on dialogue and understanding is essential, because it…
We do see a will and an intent from stakeholders, from government to physician groups, for the UK to be a global leader in life sciences.…
"We believe that by providing useful clinical decision support tools (linked to our scanning devices) to expert clinicians, we can increase their efficiency by enabling them…
"Recently, against all odds, amid the Brexit turmoil, we were awarded a EUR 4m single company grant by Horizon2020. This was instrumental in taking a decision…
"It is Gilead’s mission to develop innovative treatments in areas of high unmet need. Nobody comes to work in a pharma company wanting to develop a…
What makes managing our joint affiliate work from an Amgen perspective is the cross-functional teamwork and the fact that the same portfolio is represented in both…
